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Introduction
Numerous studies have examined the relation of risk factors
for atherosclerosis and thrombosis with the occurrence of
myocardial infarction, particularly among middle-aged and
older adults. However, few studies have examined the joint
effects of these risk factors on the risk of myocardial infarc-
tion. Given the characteristic athero-thrombotic pathology of
myocardial infarction. it is reasonable to speculate that the
joint effects of atherosclerotic and thrombotic risk factors on
the risk of myocardial infarction may be greater than the
effects of these factors considered separately.
In this paper, we review the pathologic, clinical, and
epidemiolgic evidence that suggests the interacüon of athero-
sclerotic and prothrombotic factors influences the risk of
myocardial infarction, particularly among the young. We sum-
marize the findings from a study of myocardial infarction in
young women that suggests that the joint effects of a
prothrombotic risk factor, factor V Leiden, and other risk fac-
tors, including smoking and obesity, on the risk of myocar-
dial infarction is particularly large (1). In the absence of other
risk factors;· the prothrombotic risk factor was not associated
with the risk of myocardial infarction. Based upon these pre-
liminary observations, we hypothesize that prothrombotic risk
factors interact synergistically with atherosclerotic risk
factors to increase the risk of myocardial infarction.
Pathophysiology of athero-thrombotic disease
Thrombosis of a coronary artery typically occurs in the
setting of coronary atherosclerosis and results in the clinical
occurrence of acute myocardial infarction (2). Recent
studies suggest that the disruption of a complex, lipid-laden,
atherosclerotic plaque precipitates the occurrence of an
occlusive coronary thrombosis (2). Additionally, myocardial
infarction frequently occurs at sites of previously nonsevere
coronary lesions (3), and the severity of coronary Stenosis
does not accurately predict the location of a subsequent coro-
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nary occlusion (4). For these reasons, it is likely that interac-
tions between atherosclerosis and thrombosis influence the
risk of myocardial infarction.
Although non-atherosclerotic causes of myocardial
infarction occur among the young, myocardial infarction in
the young usually occurs in the presence of coronary athero-
sclerosis and thrombosis (5,6). Among young adults who
experience myocardial infarction, the prevalences of both nor-
mal coronary artery anatomy (ränge 8-17 percent) and
single-vessel disease (ränge 32 to 62 percent) are higher and
the prevalences of severe (>70% Stenosis) and multivessel
disease lower than among older adults with myocardial
infarction (6). In short, the contribution of thrombosis to
athero-thrombotic disease may be particularly important in
the young.
Factors reiated to myocardial infarction
Both older age and male gender are strongly associated with
the incidence of myocardial infarction: myocardial infarc-
tion is rare among persons less than 45 years of age and the
incidence is particularly low among young women (7). Among
the young, myocardial infarction occurs rarely in the absence
of majorcoronary heart disease (atherosclerotic) risk factorsi
and, multiple risk factors, including current smoking,
obesity, hypercholesterolemia, hypertension, and diabetes, are
typically present (8,9). These factors also are associated with
the risk of myocardial infarction among the middle-aged;
however, the associations, äs reflected by estimates of
relative risk, are particularly large among young persons.
The risk factors associated with myocardial infarction in
the young differ among those with and without obstructive
coronary (atherosclerotic) disease (10). Among cases of myo-
cardial infarction in the young with obstructive coronary
artery disease, there were high prevalences of cigarette smok-
ing, hypercholesterolemia and hypertension (10). In contrast,
the sole major risk factor identified among cases of myocar-
dial infarction in the young with normal coronary arteriograms
was heavy smoking (10).
Studies conducted in the 1960's and 1970's demonstrated
that among premenopausal women, a particularly low
incidence population, the current use of the high dose
(estrogen) oral contraceptives was associated with a particu-
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larly large increase in the risk of myocardiai infarction among
current smokers (11,12). High dose (cstrogen) oral contra-
ceptives have multiple potenüal adverse (lipid, glucose, and
hemostasis) metabolic effects, and cigarette Smoking is asso-
ciatcd with both atherosclerosis and thrombosis. Of notc. the
joint effecls of the use of high dose oral contraceptives and
current smoking was far greater than the separate effects of
these factors: an observation that was consistent with a
synergistic interaction.
result in severe hypercholesterolemia account for a only small
Proportion of the cases of myocardiai infarction, even among
the young. Elevated levels of lipoprotein (a), another factor
that is determined, at least in part, by genetic factors, also
may increase the risk of atherosclerosis and/or thrombosis
and are related to the risk of myocardiai infarction in the young
women(lö). However, among middle-aged populations,
findings related to a possible relation between Lp(a) and tiie
risk of myocardiai infarction have been inconsistent (17).
Frequency of risk factors for atherosclerosis
The prevalences of risk factors for atherosclerosis vary by
age and gcndcr. The prevalences of risk factors related to
atherosclerosis, including obesity, hypercholesterolemia, hy-
pertension, and diabetes, increase markedly during middle-
age, possibly because of an age-related increase in viseral
adiposity and a decline in physical activity (7). In contrast,
the prevalence of current cigarette smoking is highest among
young adults and lowest among the elderly, in part, because
of the impact of smoking on survival and the higher quit rates
among older adults. Among women, menopause is associ-
ated with both changes in risk factor levels and an increase in
the risk of myocardiai infarction (13). For oral contracep-
tives, the prevalence is highest among younger pre-meno-
pausal women and declines to less than 4 percent among
women ages 4CM4 in the USA (7).
Familial aggregation of myocardiai infarction
The association of the family history of myocardiai infarc-
tion at an early age in a first-degree relative with the occur-
rence of myocardiai infarction is particularly strong among
the young (14). However, the extent to which the observed
familial aggregation of myocardiai infarction among the
young reflects shared genetic factors, shared environmental
factors, or the interaction of shared genetic and environmen-
tal factors within families remains unknown. Because myo-
cardiai infarction is a complex disease, it is unlikely that a
single gene or several genes explain the occurrence of myo-
cardiai infarction, even among the young. Given the strong
association of behavioral risk factors, such äs cigarette smok-
ing and physical inactivity, and metabolic risk factors, such
äs obesity, hypercholesterolemia, hypertension, and diabe-
tes, with the risk of myocardiai infarction, it is reasonable to
speculate that multiple genetic and environmental factors in-
teract in the etiology of myocardiai infarction.
Genetic factors and atherosclerosis
In general, heritable factors related to atherosclerosis may be
more important in the young than in the old (15). Hereditary
abnormalities of lipid and lipoprotein metabolism, such äs
familial hypercholesterolemia, are associated with an in-
creased risk of premature atherosclerosis and myocardiai in-
farction. While moderate elevations of LDL-cholesterol are
associated with atherosclerosis, the rare genetic disorders that
Risk factors for thrombosis
Among middle-aged men, markers of hemostatic risk have
been associated with the risk of myocardiai infarction. In the
Northwick Park Heart Study, both the levels of factor VII
coagulant activity and plasma fibrinogen were associated with
an increased risk of non-fatal myocardiai infarction and
ischemic heart disease death among middle aged men,
especially during the first 5 years of follow-up (18). Of note,
the risk of ischemic heart disease associated with high
fibrinogen was greater in younger than in older men (18).
Plasma D-dimer levels at the upper end of the distribution
were associated with an increased risk of myocardiai infarc-
tion among middle-aged men in the Physicians Health Study
(19), suggesting that activation.of the endogenous fibrino-
lytic System may occur long in advance of the coronary
occlusion that results in acute myocardiai infarction. How-
ever, after adjustment for total and HDL cholesterol, the
increase in risk associated with a high D-dimer level was no
longer staüstically significant (19). Elevated endogenous
üssue-type plasminogen activator (t-PA:ag) and its primary
inhibitor, plasminogen activator Inhibitor type one (PAI-1)
also were directly associated with the risk of myocardiai
infarction in the Physicians Health Study, particularly among
younger men (20).
Whether markers of the balance of the coagulation and
fibrinolytic Systems are independently related to the risk of
myocardiai infarction remains unclear, in part, because the
levels of these hemostatic markers are associated with both
other risk factors and atherosclerosis (21-32). For example,
plasma fibrinogen is associated with other risk factors, sueh
äs smoking and physical inactivity, and fibrinogen also is a
marker of underlying low-grade inflammation. Obesity, lipids,
alcohol consumption, estrogen replacement therapy,
gemfibroziland angiotensin converting enzyme inhibitors are
associated with the endogenous fibrinolytic balance (24-30).
In general, behavioral changes aimed at reducing blood
pressure and improving lipid profiles, including exercise, diet,
and moderate alcohol consumption, also may result in
favorablealterations in Factor VII activity andPAI-1 (21-23).
Genetic mutations and thrombosis
Several studies have examined the association of genetic
mutations related to thrombotic markers, such äs the Beta-
fibrinogen gene andPAI-I promoter, with myocardiai infarc-
tion (33-35). Beta-fibrinogen G/G genotype was associated
with a two fold increase in the risfc of myocardiai infarction;
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and, the association with coronary artery disease was
particularly strong among women (33). In a Swedish study
among men <45 years old, thc 4G aJlelc in thc promoter of the
plasminogen activator Inhibitor gene was associated with a
two-fold increase in the risk of myocardial Lnfarction (35). How-
ever, the 4G/5G polymorphism in the promoter of thc PAI-1
gene was not associated with myocardial infarction among the
participants in the Physicians Health Study (34). Additionally,
several studies have examined the relation of a polymoφhism
of platelet glycoprotein nia with the risk of myocardial infarc-
tion, but the results have been inconsistent (36-38). The
Physiologie consequences of the polymorphism of the platelet
glycoprotein lila remain unclear; for this reason, it is unclear
whether there is a plausible pathophysiological mechanism for
an associaüon with myocardial infarction (39).
Although deficiencies of protein C (PC), protein S (PS),
and antithrombin (AT) are uncommon, these deficiencies are
associated with venous thrombosis (40,41). Whether deficien-
cies of PC, PS and AT are associated with the risk of myocar-
dial infarction among the young remains unclear. The
carriership of Factor V (Leiden) mutant gene related to
resistance to activated protein C occurs in 4-5 percent of the
populaüon; and it is clearly associated with an increased risk
of venous thrombosis (42). However, findings of studies that
have examined the association between factor V-Leiden and
the risk of myocardial infarction are inconsistent (1,43).
Recently, we explored the role of factors related to throm-
bosis and other factors potentially related to atherosclerosis
in the etiology of myocardial infarction among young women,
18-44 years of age. As part of a population-based case-
control study of low-dose estrogen oral contraceptives and
the incidence of myocardial infarction, we examined whether
factor V Leiden, a recently identified genetic marker related
to thrombosis, was associated with the risk of myocardial
infarction among young women; and, whether other factors
modified the risk associated with the presence of the factor V
mutation (1). We demonstrated that this relatively common
prothrombotic genetic abnormality increased the risk of
myocardial infarction among young women only in the
presence of other risk factors. Below, we summarize the
major findings of this study of the determinants of myocar-
dial infarction in young women.
Risk factors related to myocardial infarction in
young women
As expected, older age, cufrent cigarette smoking, obesity,
hypercholesterolemia, hypertension, diabetes, family history
of premature myocardial infarctionj and post-menopausal
(surgically menopausal) Status were strongly associated with
the risk of incident myocardial infarction among the young
women (Table 1). Of note, 75 percent of the women who
experienced a myocardial infarction were current smokers
and 58 percent were obese. The prevalence of current use of
low-dose estrogen oral contracepüves was lower among the
cases than the controls; and, current use of low-dose estrogen
oral contraceptives was not associated with an increased risk
of myocardial infarction Overall or among older pre-meno-
Tjble 1. Charactenstics of MI patients and control subjects
Patients with MI Controls
(n=79) (n=3S8)
Age (yr)
Mean
Mediän
Range
Ethnicity (%)
White, not Hispanic
African American
Other
Current smokers (%)
Obesity (%)
Hypertension (%)
Hypercholesterolemia (%) -
Diabetes mellitus (%)
Post-menopausal (%)
Current oral contraceptive use (5)
First degree relative risk
history of MI (%)
Frequency of vigorous exercise (%)
> 3 times/week
Some but < 3 ümes/week
None
39.7
41.0
23-44
87.3
6.3
6.3
74.7
58.2
34.2
41.8
15.2
32.9
5.1
54.4
7.7
23.1
69.2
372
390
19-44
89.1
2.3
8.6
22.4
27.0
9.5
15.7 '"
2.8
11.1
10.6
29.8
24.2
39.8
35.9
Table 2. Factor V Leiden among MI patients and control subjects
Factor V Leiden (AG)
Factor V wild type (GG)
Patients with MI
• (n=79)
8 (9.5)
71 (90.5)
Controls
(n=388)
16(4.1)
372(95.9)
pausal women, current smokers, or women with other risk
factors, including obesity, hypercholesterolemia, hyperten-
sion, and diabetes. The presence of the factor V Leiden
mutation, factor V R506Q, was higher among the women
who suffered a myocardial infarction (9.5%) compared to c
ontrols (4.1%) (Table 2). After adjustment for age, factor V
Leiden was associated with a 2.4 fold increase in the risk of
myocardial infarction. Further restriction of the sample to
caucasian women, pre-menopausal women, or women not
using oral contraceptives altered only slightly the age-adjusted
odds ratio associated with the presence of factor V Leiden.
After further adjustment for current smoking, obesity,
hypercholesterolemia, hypertension, and diabetes, the
presence of factor V Leiden was associated with a four-fold
increase in the risk of myocardial infarction (1).
The increasedriskof myocardial infarction associated with
the presence of factor V Leiden was observed only among
current cigarette smokers (Table 3). Among women who did
not smoke, factor V Leiden was not associated with an
increased risk of myocardial infarction; and, among women
who smoked, factor V Leiden was associated with a 3 fold
increase in the risk of myocardial infarction. Compared to
women who did not smoke and did not carry the factor V
Leiden mutation, women who both smoked and carried the
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Table 3. Factor V Leiden and current smoking: separate and
combincd effccts on MI
Current
smokmg
no
no
yes
yes
Factor V
Genotype
Wildtype
Leiden
Wildtype
Leiden
Patienis
with MI
(n=79)
19
1
52
7
Controls
(n=388)
288
13
84
3
OR1
1
1.3
9.4
29.9
Cl 95%
(0.2 - 10.2)
(5.2 - 16.9)
(7.0-128.2)
1
 All odds ratios arc age-adjustcd and arc relative to the referencc
catcgory: those who did not smoke and did not carry tlie mutation.
Table 4. Factor V Leiden and obesity: separate and combined
effects on MI
Obesity1
no
no
yes
yes
Factor V
Genotype
Wildtype
Leiden
Wildtype
Leiden
Patients
with MI
(n=79)
29
4
42
4
Controls
(n=388)
267
14
102
2
OR2
1
2.5
3.7
19.3
CI 95%
(0.8- 8.0)
(2.2- 6.3)
(3.3-111.5)
1
 Obesity defined äs present if BMI > 215.
2
 All odds ratios are age-adjusted and are relative to the reference
category: those who were notobese and did not carry the mutation.
mutation had a 30 fold increase in their risk of myocardial
infarction.
The risk of myocardial infarction associated with obesity
also was modified by the factor V Leiden mutation (Table 4).
In the absence of the mutation, obesity was associated with a
4 fold increase in the risk of myocardial infarction. However,
obesity was associated with an 19 fold increase in the risk of
myocardial infarction in the presence of factor V Leiden. Of
note, each of the 4 non-obese women who were carriers of
the factor V Leiden mutation and experienced a myocardial
infarction were current smokers.
Similarly, the presence of one or more metabolic risk
factors, including obesity, hypercholesterolemia, hyperten-
sion, and diabetes, altered the risk associated with the
presence of factor V Leiden (Table 5). In the absence of these
factors, factor V Leiden was not associated with an increased
risk of myocardial infarction. Compared to women who had
none of these risk factors and who did not have factor V
Leiden, the presence of one or more of these metabolic risk
factors was associated with a five fold increase in the risk of
myocardial infarction in the absence of factor V Leiden and a
22 fold increase in risk in the presence of factor V Leiden. In
short, the presence of factor V Leiden increased the risk among
women with one or more metabolic risk factor by four fold.
Discussion
Because of the small number of patients with myocardial
infarction and the low prevalence of factor V mutant gene
carriers, the preliminary fmdings summarized above should
be considered äs hypothesis generating rather than hypoth-
esis testing. The statistical power to detect interactions in the
•study was limited; and, the clustering of risk factors limited
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Table 5. Factor V Leiden and metabolic risk factors: separate and
combined effects on MI
Risk Factors' Factor V
Genotype
Patients Controls OR2
with MI (n=388)
CI 95%
(n=79)
none
none
one or more
one or more
Wildtype
Leiden
Wildtype
Leiden
14
0
57
8
208
11
161
5
1
0
5.0
22.2
(0 - 6.7)
(2.7- 9.4)
(6.4-77 .5)
1
 Eitherobesiry (BMI> 27.3) ordiagnosed hypercholesterolonemia,
hypertension, diabetes, or combination of these factors.
2
 All odds ratios are age-adjusted and are relative to the reference
category: those who did not have any of these four risk factors and
did not carry the mutation.
the ability to examine combinations of factors separately.
Nevertheless, the findings summarized above suggest that
among young women factor V Leiden carriership was asso-
ciated with an increased risk of myocardial infarction only
when other risk factors a>e present. Current smoking and
metabolic risk factors were strongly associated with the risk
of myocardial infarction among women who did not carry
the factor V mutant gene, however, the risk associated with
these factors was increased markedly in the presence of the
mutant prothrombotic gene.
We explored whether the risk associated with factor V
Leiden, a prothrombotic factor, was altered by current smok-
ing, in part, because early studies of users of high dose-estrogen
oral contraceptives suggested that among smokers there was a
large increase in the risk of myocardial infarction, possibly be-
cause of a prothrombotic effect of oral contraceptives (11,12).
As expected, the prevalence of current smoking was 22 percent
among controls; and, urrent smoking was strongly associated
with the risk of myocardial infarction among young women.
While cigarette smoking was associated with an increased risk
of myocardial infarction in the absence of factor V Leiden, the
presence of the mutation increased the already higher risk among
current smokers three fold. Whether other prothrombotic
mutations in coagulation factors, such äs a recently identified
prothrombotic mutation in factor Π, also interact with cigarette
smoking and increase substantially the risk of myocardial
infarction among young women remains unknown (44). ~
We also explored whether a prothrombotic risk factor,
factor V Leiden, altered the risk associated with atheroscle-
rotic risk factors, including obesity, hypercholesterolemia,
hypertension, and diabetes. The combined prevalence of one
or more of the atherosclerotic risk factors among controls
was 44 percent; and, the presence of one or more of these
risk factors was strongly associated with the risk of myocar-
dial infarction. As noted above, the presence of factor V
Leiden increased the risk associated with the presence of one
or more of the metabolic risk factors by four fold.
Both atherosclerosis and thrombosis contribute to
the occurrence of myocardial infarction among the young
(äs well äs latter in life). With the Identification of the
genetic mutations related to the physiologic abnormalities that
lead to familial thrombophilia, there now is the opportunity
to explore potential interactions of atherogenic and
prothrombotic risk factors in the etiology of myocardial
»i
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infarction. In the Physicians Health Study, factor V Leiden
was not associated with the incidence of myocardial
infarction (43). However, the Physicians Health Study
.focused on male physicians, aged 40-84 years; and, among
the participants, there were low prevalences of current
smoking and other risfc factors and high prevalences of factors
related to a healthy lifestyle, such äs regulär exercise and
moderate alcohol consumption. It also is unclear whether the
f indin gs related to factor V Leiden observed in the population-
bascd study among young women summarized above should
be generalized to older women and men.
Since few cases of myocardial infarction among young
women (<5%) occurred among non-smokers who were free
of other risk factors for coronary heart disease, efforts to
identify factors that increase the risk among those with other
risk factors is of particular importance. As we suggest, these
efforts may identify persons at particularly high risk of
myocardial infarction äs a result of the joint effects of a
genetic predisposition to thrombosis and risk factors for
atherosclerosis. Of even greater importance, the investiga-
tion of interactions between prothromboüc factors and other
determinants of myocardial infarction among the young may
provide clues to potential interactions that contribute to the
occurrence of myocardial infarction latter in life.
The occurrence of myocardial infarction is multi-causal. In
addition to heritable factors, lifestyle factors., such äs diet,
exercise, and smoking, contribute to the risk'of myocardial
infarction. The effects of these behaviors may be mediated, in
part, through effects on the levels or activity of factors related
to coagulation, fibrinolysis, or platelet function or these factors
may modify the effects of hemostatic factors. Additionally, these
and other factors, such äs infection with chlamydiapneumonae,
herpes Simplex Type l, and cytomegalovirus, may alter coro-
nary vessel walls and plaque stability.and, thereby, increase the
risk of athero-thrombotic disease.
Recently, attention has focused on events that might
trigger the occurrence of myocardial infarction (45). As in
venous thrombosis, it is unlikely that acute myocardial
infarction occurs spontaneously. In the presence of both
atherosclerosis and a prothrombotic factor, a triggering event
may precipitate an acute myocardial infarction. For exam-
ple, it is possible that prothrombotic factors influence the risk
of exercise-reläted myocardial infarction among middle-aged
men with atherosclerosis (46).
Additional observational studies are needed to explore
Potential interactions between behavioral factors (smoking,
diet, and physical activity.), metabolic factors (obesity,
hypercholesterolemia, hypertension, and diabetes) and
common prothrombotic genetic mutations. Future research
should examine interactions between atherogenic risk
factors and newly identified prothrombotic mutations. DNA
poly-morphisms that result in physiologic consequences
related to thombosis are not altered by other risk factors,
subclinical coronary artery disease, or the occurrence of
myocardial infarction. For this reason, retropective popula-
tion-based case control studies can be used to examine
potential interactions in low-risk populations, such äs young
women and men.
Summary
Myocardial infarction in the young provides a unique model
for the investigation of potential interactions between athero-
sclerotic and prothrombotic risk factors. Because myocardial
infarction reöects athero-thrombotic disease, it is important
to take into account factors related to atherosclerosis when
examining prothrombotic factors äs potential determinants
of myocardial infarction. In Western societies, there are
increases in both the prevalences of metabolic risk factors
and atherosclerotic coronary disease with aging. The clinical
expression of the thrombotic risk associated with heritable
factors, such äs factor V Leiden, äs myocardial infarction
appears to occur only in the presence of other risk factors,
such äs smoking and known metabolic risk factors related to
atherosclerosis.
If confirmed in other studies of factor V Leiden and with
other mutations related to prothrombotic risk, these observa-
tions will likely have both etiologic and practical conse-
quences. Finally, we suggest that efforts to determine whether
a prothrombotic risk factor contributes "independently" to
the risk of myocardial infarction may lead to a significant
underestimation of the importance of the factor in the
occurrence of myocardial infarction, particularly among
clinically-important subsets of the population.
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